AGIOS PHARMACEUTICALS, INC.

Key metrics

Financial performance

Over the last 9 fiscal years AGIOS PHARMACEUTICALS, INC.'s revenue declined from $69.89M to $54.03M, a compound annual decline rate of 2.8%. Net profit margin compressed from -284.0% to -764.4% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (1,268 filings)

Recent press releases

• Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib2026-06-01

  Agios obtains exclusive global rights to novel, late-stage, next-generation, oral SYK inhibitor

• Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes2026-05-29

  Results did not meet predefined threshold to support further development in LR-MDS

• Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia2026-05-22

  PYRUKYND is the only medicine approved in the EU for adults with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia

• Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias2026-05-12

  Detailed results from RISE UP Phase 3 trial of mitapivat in sickle cell disease selected for distinguished Plenary Abstracts Session

• Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease2026-05-12

  sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway

Similar companies

The largest companies sharing AGIOS PHARMACEUTICALS, INC.'s SEC industry classification (pharmaceutical preparations).